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LIFETIME HEALTH CARE COSTS OF OBESITY-RELATED COMORBIDITIES IN THE 
UNITED STATES, 2007-2010
Chang S, Leung MY, Carlsson NP, Colditz GA
Division of Public Health Sciences, Department of Surgery, Washington University School of 
Medicine, St. Louis, St. Louis, MO, USA
OBJECTIVES: This study analyzed lifetime healthcare costs of obesity-related 
comorbidities, including diabetes, hypertension, coronary heart disease (CHD), 
and stroke. METHODS: We used data from the National Health Interview Survey 
(NHIS), 2007-2010, and linked it to the Medical Expenditure Panel Survey to esti-
mate annual healthcare expenditures. We excluded pregnant women, cancer 
survivors, and underweight individuals. Disease risks were estimated using the 
National Health and Nutrition Examination Survey data. Mortality risks were 
estimated using the NHIS Linked Mortality Public-Use Files and predicted for 
the 2007-2010 population. Analyses were stratified by gender and controlled for 
age, race, body mass index (BMI) category, comorbidities, smoking, and insur-
ance. Complex sampling designs were adjusted for. A Markov model, populated by 
disease and mortality estimates and healthcare expenditures, was built to simu-
late lifetime healthcare expenditures for gender-race-age-BMI group subpopula-
tions. RESULTS: We included 18,763 women and 14,793 men. We use insured, 
non-smoking individuals age 40 as an example. Without obesity-related comor-
bidities, remaining lifetime healthcare costs ranged from $90,125 (normal-weight, 
non-white, non-black men) to $149,761 (obese white women). With diabetes, costs 
ranged from $124,757 (overweight, non-white, non-black men) to $207,643 (obese 
white women); with hypertension, costs ranged from $118,084 (overweight, non-
white, non-black men) to $197,343 (obese white women); with CHD, costs ranged 
from $141,753 (normal-weight, non-white, non-black men) to $225,575 (obese black 
men); with stroke, costs ranged from $107,803 (normal-weight, non-white, non-
black men) to $184,283 (obese white women). With two comorbidities, obese black 
men with hypertension and CHD had the highest costs ($274,104). With three 
comorbidities, obese white women with diabetes, hypertension, and CHD incurred 
the highest costs ($357,486). With all four comorbidities, obese white women had 
the highest costs ($432,102). CONCLUSIONS: This study suggests that obesity-
related comorbidities impose a significant economic burden. Some subpopula-
tions, e.g., obese white women and obese black men, incur higher healthcare 
costs than others.
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THE ASSOCIATION BETWEEN ADHERENCE TO CARDIOVASCULAR MEDICATIONS 
AND HEALTH CARE UTILIZATION
Simon-Tuval T1, Triki N2, Chodick G3, Greenberg D1
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Maccabi Healthcare Services, Tel-Aviv, 
Israel, 3Maccabi Healthcare Services and Tel-Aviv University, Tel-Aviv, Israel
OBJECTIVES: Poor adherence to medications for cardiovascular disease (CVD) is 
associated with adverse health outcomes, but little is known on its impact on 
healthcare utilization (HCU). We examined whether adherence is related to a long-
term decrease in HCU. METHODS: A retrospective cohort study of 2220 patients with 
CVD enrolled in Maccabi Healthcare Services in Israel initiating CVD medication 
therapy between 2006 and 2008. Adherence was assessed by the proportion of days 
covered (PDC) with medications. Patients were defined as: non-adherent (PDC< 0.4), 
partially adherent (0.4≤ PDC< 0.8), and adherent (PDC≥ 0.8). HCU was estimated fol-
lowing treatment initiation and up to four years. Multivariable GEE models were 
used to analyze predictors of HCU. Model I included total adherence during the 
entire follow-up period as well as the interaction between this measure and the 
follow-up year. Model II included previous and current year’s adherence as well 
as previous year’s HCU cost. Both models were adjusted to potential confounders 
including: age, gender, socioeconomic status, ownership of voluntary supplemen-
tary health insurance, and comorbidities. RESULTS: The median age of patients 
was 63 (67% males). Fifty one percent of patients (n= 1139) were defined as adher-
ent, 24% as partially adherent and 25% as non-adherent. Model I: The annual HCU 
costs of adherent patients decreased in 9% following treatment initiation (RR= 0.91, 
95% confidence interval (CI): 0.88-0.95, P< 0.001). This decrease stem predominantly 
from reduction in hospitalization and medication costs. No significant changes in 
annual costs following treatment initiation were observed among partially adherent 
(RR= 0.97, 95% CI: 0.88-1.07, P= 0.526) and non-adherent (RR= 0.99, 95% CI: 0.90-1.09, 
P= 0.785) patients. Model II: No temporal association was found between adherence 
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and HCU. CONCLUSIONS: Adherence to CVD medications is suboptimal. Adherence 
is associated with long-term decrease in healthcare expenditure. Exploring reasons 
for the high non-adherence and ways to improve adherence may optimize utiliza-
tion of health systems’ scarce resources.
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PREVALENCE AND DIRECT MEDICAL COSTS ASSOCIATED WITH ANGINA AND 
CHEST PAIN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN THE 
UNITED STATES
Machacz S1, Bonafede 2, Wade S3, Stephens L1, Hernandez J1
1Abbott Vascular, Santa Clara, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Wade 
Outcomes Research and Consulting, Salt Lake City, UT, USA
OBJECTIVES: Percutaneous coronary intervention (PCI) is effective in reducing 
angina and improving quality of life. However, as reported in clinical trials, angina 
and chest pain remain a clinical challenge post-PCI. Currently there is limited 
contemporary data on the real world rate and its economic burden. We sought to 
describe the incidence and direct costs associated with angina or chest pain fol-
lowing a PCI. METHODS: Patients undergoing PCI (index event) were identified in 
the Truven Health MarketScan Commercial and Medicare Supplemental Databases 
from 2008-2011. Patients were required to have 12 months of continuous enroll-
ment pre- and post-index. Post-index angina and chest pain were defined as an 
inpatient claim with a principal diagnosis of angina or chest pain, an outpatient 
claim with an angina or chest pain diagnosis with an accompanying stress test, 
repeat PCI or cardiac catheterization, more than one month post-index. Total and 
cardiovascular-specific costs were described 1-3 years post-index in 2013 US$. 
Patients with post-index acute coronary syndrome (ACS) were excluded from the 
cost analysis. RESULTS: 51,756 patients met the selection criteria (mean age: 61.8 
years, 72% male). The incidence of post-PCI angina or chest pain was 27.8% by one 
year increasing to 40.1% by three years post-PCI. Average total costs for angina/chest 
pain patients were 1.8 times higher (+$14,514) than those without angina, chest pain 
or ACS (p< 0.001) with differences persisting at three years (p< 0.001). Post-PCI cardi-
ovascular-related costs were likewise higher for angina/chest pain patients one year 
($18,548 (SD= $30,525) versus $7,896 (SD= $17,638), p< 0.001) and three years post-
index ($33,238 (SD= $43,261) versus $19,773 (SD= $34,097), p< 0.001). CONCLUSIONS: 
Post- PCI angina and chest pain are common and carry substantial direct medical 
burden. Strategies to reduce these events could impact the costs and improve out-
comes of ischemic heart disease.
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OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH 
HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC 
MEDICAL CENTER (AMC) IN THE UNITED STATES
Bress A1, King J1, Singhal M1, Brixner D1, Kielhorn A2, Patel H2, Maya J2, Biskupiak JE1, 
Munger M1
1University of Utah, Salt Lake City, UT, USA, 2Amgen, Thousand Oaks, CA, USA
OBJECTIVES: To assess clinical characteristics, hospitalizations, and hos-
pitalization charges among a contemporary, real world cohort of HFrEF 
patients. METHODS: A retrospective cohort study of HFrEF, identified by ICD-9 
code 428.x with a left ventricular ejection fraction (LVEF) ≤ 40% between 01/01/08 
to 12/31/13 (study period) were identified using an AMC enterprise data warehouse 
(EDW) that includes electronic health records and billing/administrative claims. 
Demographic, clinical, and hospitalization/charge data were extracted. The index 
date was defined as the first mention of an ICD-9 of 428.x within the study period. 
A subset of prevalent HFrEF underwent chart review to obtain detailed medica-
tion and medical histories. RESULTS: The cohort comprised 1931 HFrEF with a 
mean age of 63±15 years, prevalently Caucasian (70%) males (70%). The average 
LVEF was 28±9%. Medication data and etiology was assessed in prevalent HFrEF 
(n= 989). The prevalent HFrEF cohort was predominantly ischemic etiology (67%) 
and ACEi/ARB/aldosterone antagonists were prescribed in 53%/16%/29%, respec-
tively. Eighty percent were on β -adrenergic blockers. Atrial fibrillation and renal 
insufficiency were present in 45% and 42%, respectively. Devices were present in 
34% (Implantable Cardioverter-Defibrillator) and 16% (Cardiac Resynchronization 
Therapy) of patients. In the full sample, during a mean follow up period of 34±26 
months, all-cause mortality was 18% (13% CV death) at one-year and 23% (16% 
CV death) at two-years. There were 2106 all-cause hospitalizations of which 972 
(46%) were for heart failure (HF). The median length of stay for HF hospitaliza-
tions was 4.3 days and the median charge was $27,230. Among the HF hospitali-
zations 30-day readmission rates were 167 (21%) for all-cause, and 111 (13%) for 
HF. CONCLUSIONS: In an AMC-based EDW, HFrEF was well treated, resulting in 
a 1-year mortality and 30-day re-admission rates similar to published data. The 
median charge for a HF hospital stay was $27,230.
